PatenSee Raises $2M Seed Funding to Revolutionize Hemodialysis Care with Contactless Surveillance Technology

PatenSee, a pioneering clinical-stage medical device company, has successfully raised $2,000,000 to advance its breakthrough contactless surveillance system. Designed to detect early signs of asymptomatic vascular stenosis in hemodialysis patients, PatenSee’s innovative solution harnesses advanced multi-modal imaging technologies in combination with machine learning. This funding will accelerate the company’s mission to provide early detection tools that enable care teams to perform simple, timely interventions, thereby protecting patients’ lifelines, elevating the quality of patient care, and ultimately prolonging life expectancy. By identifying emerging stenosis risks at the earliest moments, PatenSee offers a powerful tool that addresses a critical need in the dialysis market—a market projected to exceed $100 billion by 2024. Founded by Hagay Drori and Oz Seadia after their participation in MEDX Xelerator’s X-Challenge competition, PatenSee has rapidly evolved from concept to clinical validation under the leadership of CEO Dr. Gal Goshen. In less than two years, Dr. Goshen successfully guided the company from its early conceptual stages to completing its first-in-human clinical study. This agile approach has showcased PatenSee’s potential to revolutionize patient monitoring through non-invasive, contactless methods, while mitigating the risks associated with traditional approaches. The recent funding is earmarked not only for further clinical studies and product refinement but also to expand regulatory pathways and market penetration within the lucrative and expanding dialysis industry. This strategic investment marks a significant milestone for both PatenSee and its investors, including its status as a seed-stage portfolio company of MEDX Xelerator, reinforcing the commitment to reshaping patient care through innovative, high-impact medical technologies.